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Summary
 
A novel human CC chemokine consisting of 78 amino acids and having a molecular mass of
8,778.3 daltons (VVIPSPCCMF FVSKRIPENR VVSYQLSSRS TCLKAGVIFT TKKGQQ
SCGD PKQEWVQRYM KNLDAKQKKA SPRARAVA) was isolated together with three
minor COOH-terminally truncated variants with 73, 75, and 76 residues. The new chemokine
was termed eotaxin-2 because it is functionally very similar to eotaxin. In terms of structure,
however, eotaxin and eotaxin-2 are rather distant, they share only 39% identical amino acids
and differ almost completely in the NH
 
2
 
-terminal region. Eotaxin-2 induced chemotaxis of
eosinophils as well as basophils, with a typically bimodal concentration dependence, and the re-
lease of histamine and leukotriene C
 
4
 
 from basophils that had been primed with IL-3. In all as-
says, eotaxin-2 had the same efficacy as eotaxin, but was somewhat less potent. The migration
and the release responses were abrogated in the presence of a monoclonal antibody that selec-
tively blocks the eotaxin receptor, CCR3, indicating that eotaxin-2, like eotaxin, acts exclu-
sively via CCR3. Receptor usage was also studied in desensitization experiments by measuring
[Ca
 
2
 
 
 
]
 
i
 
 changes in eosinophils. Complete cross-desensitization was observed between eotaxin-2,
eotaxin and MCP-4 confirming activation via CCR3. No Ca
 
2
 
 
 
 mobilization was obtained in
neutrophils, monocytes and lymphocytes, in agreement with the lack of chemotactic respon-
siveness. Intradermal injection of eotaxin-2 in a rhesus monkey (100 or 1,000 pmol per site) in-
duced a marked local infiltration of eosinophils, which was most pronounced in the vicinity of
postcapillary venules and was comparable to the effect of eotaxin.
 
L
 
eukocyte recruitment in inflammation and immunity is
regulated by a large number of CXC and CC chemo-
kines (1). In the past few years several new proteins of this
class have been discovered and considerable information
has been gained about the functions of the known ones. It
has been shown in particular that the monocyte chemotac-
tic proteins (MCP-1, MCP-2, MCP-3, and MCP-4) do not
only act on monocytes, as their name suggests, but also on
lymphocytes (2, 3) and basophils (4, 5), and that MCP-2,
MCP-3 and MCP-4 are potent attractants for eosinophils
(6–8).
Eosinophilia and tissue infiltration by eosinophils are fre-
quently observed in allergic inflammation and parasitic dis-
eases (9). The mechanisms by which these cells are re-
cruited and activated is widely studied because of the
pathological consequences resulting from the release of
their phlogogenic and cytotoxic products. The challenge is
to understand the selectivity of the chemotactic process and
to develop efficient inhibitors. Several factors have been
proposed as eosinophil attractants such as the anaphylatoxin
C5a (10), platelet-activating factor (11), and more recently
RANTES (12) and IL-16 (13). None of these stimuli is se-
lective, however, and the discovery of eotaxin, which was
originally shown to attract only eosinophils and to be spe-
cific for a single chemokine receptor, CCR3 (14–16), was
greeted as a promising advance (17).
Within a large-scale sequencing and expression program
for the discovery of new chemokines, we have recently
identified MCP-4, a CC chemokine with powerful effects
on eosinophils (8). In this paper, we describe a chemokine
that is also active on eosinophils and is functionally very
similar to eotaxin. It attracts and activate human eosino-
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phils and basophils via the eotaxin receptor, CCR3, and
has no activity on other leukocytes. Because of these prop-
erties, we have named the novel chemokine eotaxin-2.
 
Materials and Methods
 
Cloning, Expression, Purification and Analysis.
 
The EST repre-
senting CK
 
 
 
-6 cDNA was identified in the database of Human
Genome Sciences Inc. (Rockville, MD) on the basis of the CC
motif and the homolgy to known CC chemokines (18). The
cDNA was isolated from a library derived from activated human
monocytes, and the mature protein was expressed in Sf9 insect
cells (CRL 1711; American Type Culture Collection, Rockville,
MD). Purification was performed by cation exchange, heparin af-
finity, and size exclusion chromatograpy (poros 50 HS, poros 20
HE1; Perseptive Biosystem; and Sephacryl S200 HR; Pharmacia)
in the presence of protease inhibitors (20 mg/ml Pefabloc SC;
Boehringer Mannheim, 1 mg/ml leupeptin, 1 mg/ml E64, and
1 mM EDTA). The purified protein was analyzed by laser des-
orption mass spectrometry (matrix-assisted laser desorption ion-
ization-time of flight) and by Edman degradation after partial
proteolysis with the endoprotease GluC (Boehringer Mannheim).
 
Chemokines.
 
Eotaxin, MCP-3, MCP-4, RANTES, and
MIP-1
 
 
 
 were used as standards. MCP-4 was cloned and ex-
pressed as described previously (8), and the other chemokines
were chemically synthesized by Dr. I. Clark-Lewis (Biomedical
Research Centre, University of British Columbia, Vancouver,
Canada) (19).
 
CCR3-blocking Antibody.
 
The anti-CCR3 monoclonal anti-
body 7B11 which selectively blocks the eotaxin receptor (20) was
kindly provided by Dr. Charles Mackay (LeukoSite Inc., Cam-
bridge, MA).
 
Cells.
 
Monocytes (21), lymphocytes (3), and neutrophils (22)
were isolated from donor blood buffy coats. The lymphocytes
were cultured in the presence of IL-2 as previously described (3).
Eosinophils (12) and basophils (23, 24) were purified from the
venous blood of healthy volunteers. The eosinophil preparations
were 
 
 
 
95% pure and the basophil preparations consisted of 70–
80% basophils and 20–30% lymphocytes.
 
[Ca
 
2
 
 
 
]
 
i
 
 Changes.
 
Changes in the cytosolic free Ca
 
2
 
 
 
 concen-
tration ([Ca
 
2
 
 
 
]
 
i
 
) were assayed in monocytes, eosinophils, lympho-
cytes, and neutrophils loaded with Fura-2 (25). Receptor desensi-
tization was tested by monitoring [Ca
 
2
 
 
 
]
 
i
 
 changes in response to
sequential stimulation with chemokines (21).
 
In Vitro Chemotaxis.
 
Chemotaxis was assessed in 48-well
chambers (Neuro Probe, Cabin John, MD) using polyvinylpyr-
rolidone-free polycarbonate membranes (Nucleopore, Neuro
Probe, Cabin John, MD) with 5-
 
 
 
m pores for eosinophils, baso-
phils, neutrophils and monocytes, and 3-
 
 
 
m pores for lympho-
cytes (3, 6). Cell suspensions and chemokine dilutions were made
in RPMI 1640 supplemented with 20 mM Hepes, pH 7.4, and
1% pasteurized plasma protein solution (Central Laboratory of the
Swiss Red Cross). Migration was allowed to proceed for 60 min
at 37
 
 
 
C in 5% CO
 
2
 
. The membrane was then removed, washed
on the upper side with PBS, fixed, and stained. All assays were
done in triplicate, and the migrated cells were counted in five
randomly selected fields at 1,000-fold magnification. Spontaneous
migration was determined in the absence of chemoattractant.
 
Histamine and Leukotriene C
 
4
 
 (LTC4) Release.
 
Basophils (0.1–
0.3 
 
 
 
 10
 
6
 
 cells/ml) in 20 mM Hepes, pH 7.4, containing 125
mM NaCl, 5 mM KCl, 1 mM MgCl
 
2
 
, 1 mM CaCl
 
2
 
, 0.5 mM
glucose and 0.025% BSA were warmed to 37
 
 
 
C, primed with 10
ng/ml IL-3 for 5 min, and then challenged with a chemokine.
The reaction was stopped on ice after 20 min and histamine and
LTC
 
4
 
 were measured in the supernatants (26). Histamine release
was expressed as percent of the total cellular content (determined
after cell lysis). LTC
 
4
 
 generation was expressed in ng per 10
 
6
 
 ba-
sophils.
 
Enzyme Release.
 
N-acetyl-
 
 
 
-
 
d
 
-glucosaminidase release was
assayed in monocytes (21) and elastase release in neutrophils (22)
exactly as described previously.
 
In Vivo Activity.
 
A male rhesus monkey of 7.5 kg was anes-
thesized by injection of 10 mg/kg Ketamine (Ketalar, Parke Davis)
i.m. and 15 mg/kg Na Thiopental (Pentotal, Abbott) i.v. The
chemokines (100 pmol eotaxin, 100 and 1,000 pmol eotaxin-2 in
100 
 
 
 
l pyrogen-free isotonic saline) were then administered in-
tradermally on the back, and full skin thickness punch biopsies of
8-mm diameter were taken from the injection sites after 4 h. The
biopsies were fixed in formalin, embedded in paraffin, and 5-
 
 
 
m
sections were prepared. The sections were stained with Giemsa
solution or hematoxylin and eosin, and the eosinophil infiltrates
were evaluated by two independent observers. In each section,
eosinophils were counted at a magnification of 630
 
 
 
 in five ran-
domly selected fields including a postcapillary venule, using a grid
of 0.19 
 
 
 
 0.19 mm, and the number of eosinophils per mm
 
2
 
 was
calculated. Photographs were taken at a magnification of 1,000
 
 
 
with a Nikon Microphot microscope (Nikon AG, Switzerland).
 
Results and Discussion
 
Eotaxin-2 Structure.
 
The purified material contained a
protein of 
 
 
 
8.5 kD, as judged on SDS-PAGE. The mate-
rial was treated with GluC under conditions ensuring cleav-
age COOH-terminally of glutamic acid, and three frag-
ments were obtained. The first two were homogeneous
and extended from residue 1 to 18 and 19 to 54, respec-
tively, while the third showed some COOH-terminal het-
erogeneity. Sequencing and mass spectrometry revealed
Figure 1. Amino acid sequences of eotaxin-2 aligned with eotaxin, MCP-3, MCP-4, MIP-1 , and RANTES. Identical amino acids are indicated by
a hyphen. The sites of COOH-terminal truncation leading to the shorter variants are indicated by arrowheads. 
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tree COOH-terminally truncated forms consisting of resi-
dues 55–73, 55–75, and 55–76 in addition to the main
form extending from residue 55 to 78 (Fig. 1). The mass of
the 78-residue form of eotaxin-2 is 8,778.3 and the amino
acid identities to reference chemokines were 43% for
MCP-4, 42% for MIP-1
 
 
 
, 39% for MCP-3 and eotaxin,
and 32% for RANTES. Since the four COOH-terminal
variants could not be separated all tests were performed
with the mixture. The sequence shown in Fig. 1 corre-
sponds to the cDNA-deduced sequence of the chemokine
MPIF-2 that was shown to inhibit the proliferation of my-
eloid progenitors (18), except for two substitutions, Ala
 
35
 
for Gly and Ser
 
47
 
 for Phe.
Figure 2. Cross-desensitization of human blood eosinophils. Fura-
2–loaded cells were stimulated sequentially at 90-s intervals with 50 nM
eotaxin-2 and another CC chemokine at the same concentration, and
[Ca2 ]i dependent fluorescence changes were recorded. The tracings are
representative for three separate experiments performed under identical
conditions with cells from different donors.
 
Leukocyte Responses and Receptor Usage.
 
[Ca
 
2
 
 
 
]
 
i
 
 changes,
were monitored in blood leukocytes after stimulation with
1 to 1,000 nM eotaxin-2. A marked, concentration-depen-
dent effect was observed on eosinophils whereas neutrophils,
monocytes and T lymphocytes did not respond. Desensiti-
zation experiments were then performed with eosinophils
to gain information on receptor selectivity. As shown in
Fig. 2, eosinophil stimulation with eotaxin-2 abrogated the
response to eotaxin, attenuated the responses to MCP-3
and RANTES, but did not appreciably affect the response
to MIP-1
 
 
 
. In agreement with these results the [Ca
 
2
 
 
 
]
 
i
 
 rise
induced by eotaxin-2 was abrogated by prior stimulation
with eotaxin, decreased by stimulation with RANTES or
MCP-3, but was not affected by MIP-1
 
 
 
. Cross-desensi-
titzation was also observed between eotaxin-2 and MCP-4
(data not shown). These results suggest that eotaxin-2 is a
selective agonist for eosinophils. The complete cross-desensiti-
zation between eotaxin-2 and eotaxin indicates that both
chemokines act mainly, if not exclusively, via CCR3. This
conclusion is in agreement with the partial desensitization
of the responses to RANTES and MCP-3, which are
known to interact with at least two additional receptors,
CCR1 and CCR2. The lack desensitization of the re-
sponse to MIP-1
 
 
 
, on the other hand rules out an interac-
tion of eotaxin-2 with CCR1.
 
In Vitro Chemotaxis.
 
As shown in Fig. 3, eotaxin-2 was
a highly effective attractant for eosinophils and basophils.
The concentration dependence was typically bimodal, and
the overall effect was similar to that of eotaxin. Maximum
migration was reached at 100 nM eotaxin-2 and 10 nM eo-
taxin which thus appears to be more potent. When the as-
say was performed in the presence of the anti-CCR3 anti-
body, eosinophil and basophil chemotaxis toward either
eotaxin or eotaxin-2 was completely prevented, indicating
that they both acted exclusively via CCR3. Eotaxin-2, like
eotaxin, did not induce migration of neutrophils, mono-
cytes and T lymphocytes, which is in agreement with the
lack of Ca
 
2
 
 
 
 mobilization observed in these cells.
 
Histamine and LTC
 
4
 
 Release.
 
In view of the marked
chemotactic activity toward basophils, the effect of eotaxin
and eotaxin-2 as inducers of release was determined (Fig.
4). Both chemokines induced a similar release of histamine
Figure 3. Chemotactic re-
sponses of human blood eosino-
phils and basophils to eotaxin
and eotaxin-2, in the presence
(open symbols) or absence (closed
symbols) of 10  g/ml anti-CCR3
added to the cells 10 min before
loading into the chemotaxis
chamber. Numbers of migrating
cells per five high power fields
are given. One out of three simi-
lar experiments performed with
cells from different donors is
shown. 
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Figure 4. (A and B) Histamine and LTC4 release by basophils pre-
treated with IL-3 in response to increasing concentrations of eotaxin and
eotaxin-2. Each symbol represents mean values from four experiments
performed with cells from different donors. (C and D) Histamine and
LTC4 release by IL-3 pretreated basophils after stimulation with 100 nM
eotaxin or eotaxin-2 in the presence (open columns) or absence (filled col-
umns) of anti-CCR3. Mean   SEM of three experiments performed with
basophils from different donors.
 
and peptido leukotrienes in IL-3 pretreated basophils from
several unselected donors. The curves relating effect to
concentration show that eotaxin was somewhat more po-
tent than eotaxin-2 in particular as inducer of LTC
 
4
 
 release.
Similar release responses were obtained with RANTES and
MIP-1
 
 
 
 (data not shown). In agreement with the data of
the chemotaxis assays, mediator release induced by eotaxin
and eotaxin-2 was markedly inhibited by pretreatment of
the cells with the anti-CCR3 antibody.
 
Effects In Vivo.
 
The ability of eotaxin-2 to act as
chemoattractant in vivo was examined in a rhesus monkey
in comparison with eotaxin. As shown in Fig. 5 
 
A
 
, 4 h after
injection of 100 pmol per site both chemokines induced a
similar, marked eosinophil infiltration whereas the vehicle
alone had no effect. The number of infiltrating eosinophils
was 
 
 
 
50% higher at sites where 1,000 pmol eotaxin-2 was
applied. The effect is remarkable because the monkey used
in this experiment had a low blood eosinophil count (0.7%
of total leukocytes). As shown by representative micro-
graphs, several infiltrating eosinophils can be recognized by
the characteristic nucleus and the Giemsa staining of the
granules. They are found in the vicinity of postcapillary
venules (Fig. 5, 
 
B
 
 and 
 
C
 
) and in association with the venu-
lar wall (Fig. 5 
 
C
 
).
This paper describes a chemokine which we have
termed eotaxin-2 because its function is perfectly analogous
to that of eotaxin. Both chemokines activate and attract
eosinophils and basophils, but no other leukocytes, and ap-
pear to act exclusively via CCR3. It must be mentioned,
however, that a virtually identical chemokine, MPIF-2,
was reported to inhibit colony formation by myeloid pro-
genitor cells (18). The functional similarity between eo-
taxin and eotaxin-2 is astonishing because these chemo-
kines share only 39% identical amino acids. In addition, they
differ almost completely within the short NH
 
2
 
-terminal se-
quence preceding the first cysteine, which has been identi-
fied as the receptor triggering region of several chemokines
Figure 5. (A) In vivo infiltration of eosinophils. A rhesus monkey received intradermal injections of eotaxin-2 (100 or 1,000 pmol per site), eotaxin
(100 pmol per site) or pyrogen-free isotonic saline. After 4 h, punch biopsies were taken and processed for histology. Eosinophils were counted on sec-
tions stained with hematoxylin and eosin (five fields per section) in areas including postcapillary venules. (B) Micrograph of a skin site 4 h after injection
of 100 pmol eotaxin-2, stained with Giemsa solution. Clearly identifiable eosinophils are seen near the inset; one is seen in contact with the venule wall.
(C) Micrograph of a skin site 4 h after injection of 1,000 pmol eotaxin-2, stained with hemaotxylin and eosin. Two eosinophils are within the venule wall
(see also inset) and others are in the lumen and in the tissue. 
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(27). It is well established that all CXC chemokines that
activate neutrophils via the IL-8 receptors, CXCR1 and
CXCR2, share a conserved Glu-Leu-Arg motif preceding
the first cysteine that tolerates only minimal substitutions
(28, 29), and it has been shown more recently that CC
chemokines drastically lose activity toward monocytes (1)
and basophils (27, 30) upon deletion of as few as one or two
NH
 
2
 
-terminal amino acids. Yet the present findings show
selective activation of the same receptor, CCR3, by two
chemokines that have only one common residue (Pro-4 of
eotaxin-2 corresponding to Pro-6 of eotaxin) in the pre-
sumed receptor triggering domain. The eotaxin sequence is
actually much more similar (
 
 
 
60% identity) to that of
MCP-3, which binds to CCR3, but also to CCR1 and
CCR2 and even to MCP-1, a selective ligand for CCR2,
which is inactive on eosinophils.
Eotaxin is an unusually selective chemokine (17). It was
discovered as attractant for eosinophils in the bronchoalve-
olar lavage fluid obtained in an experimental model for
lung allergy in guinea-pigs (17, 31) and subsequently
shown to occur in mice (32) and humans (15) as well. The
present discovery of a chemokine that shares with eotaxin
receptor specificity, in vitro activities on eosinophils and
basophils, and the ability to elicit eosinophil infiltration in
vivo reveals the existence of a mechanism for the concom-
itant and selective recruitment of the two types of granulo-
cytes that are characteristic of allergic inflammation.
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